Cancer Treatment: are treatments that may include surgery, chemotherapy, and radiation therapy. If your cancer is particularly sensitive to radiation therapy or chemotherapy, you may receive one of those therapies as your primary treatment. Adjuvant treatment.
DATE: March 22, 2018TIME: 09:00am PST, 12:00pm ESTGlioblastoma (GBM) is the most aggressive primary brain cancer, with nearly universal recurrence after treatment. GBMs are highly heter...
DATE: February 22, 2018TIME: 09:00am PST, 12:00pm EST, 06:00pm CEST(Europe)Colorectal cancer (CRC) develops during a multi-step process from small lesions of the intestinal epithelium....
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
This lecture introduces the evolving paradigm of Molecular Pathological Epidemiology (MPE) as simply as possible. Any given human disease represents fundamentally heterogeneous process,...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for ca...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
DATE: October 19, 2017TIME: 7:00 AM PDT, 10:00 AM EDT, 4:00 PM CETThis is the second topic in the webinar series on ‘Sanger Sequencing & Fragment Analysis made easy’...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
In order to expand the treatment options of cancers driven by oncogenic RAS, new cell surface targets need to be identified and characterized. Here, we describe mass spectrometry based phenot...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
Nanopore sequencing has enormous potential for application to cancer, but specifically offers advantages into two main arenas, epigenetics and structural variation. Methylation is well-known...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not...
DATE: March 22, 2018TIME: 09:00am PST, 12:00pm ESTGlioblastoma (GBM) is the most aggressive primary brain cancer, with nearly universal recurrence after treatment. GBMs are highly heter...
DATE: February 22, 2018TIME: 09:00am PST, 12:00pm EST, 06:00pm CEST(Europe)Colorectal cancer (CRC) develops during a multi-step process from small lesions of the intestinal epithelium....
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
This lecture introduces the evolving paradigm of Molecular Pathological Epidemiology (MPE) as simply as possible. Any given human disease represents fundamentally heterogeneous process,...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for ca...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
DATE: October 19, 2017TIME: 7:00 AM PDT, 10:00 AM EDT, 4:00 PM CETThis is the second topic in the webinar series on ‘Sanger Sequencing & Fragment Analysis made easy’...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
In order to expand the treatment options of cancers driven by oncogenic RAS, new cell surface targets need to be identified and characterized. Here, we describe mass spectrometry based phenot...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
Nanopore sequencing has enormous potential for application to cancer, but specifically offers advantages into two main arenas, epigenetics and structural variation. Methylation is well-known...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not...
Follow
